Quality of Life and Neurocognitive Functioning

Summary

Studying QoL in patients DLGG receiving TMZ is complex because of the multiples interactions between tumor characteristics, neurocognitive functioning, treatments, environment and psychopathological context in which these patients experience symptoms. It is, however, important to accurately evaluate these aspects in consideration of the young age, generally preserved QoL at the time of diagnosis, possible implications of the disease on the professional (DLGG patients are often still active), social and familial domain, and relatively long survival of these patients. In the absence of a curative treatment for DLGG, preserving patients' QoL is indeed a major goal.

Timeline

Start

2017-07-27

Primary completion

2021-11-26

Completion

2021-12-31

Publications

• Results Darlix A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas E, Carriere M, Menjot-de-Champfleur N, Rigau V, Duffau H, Guerdoux E. Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study. Neurooncol Adv. 2024 Jun 4;6(1):vdae084. doi: 10.1093/noajnl/vdae084. eCollection 2024 Jan-Dec.

Drugs

Indications